PAT-SM6, a natural human antibody drug developed by Australia's Patrys Limited has †prevented colon cancer metastases in a series of recently completed preclinical animal studies.† Clinical trials on humans are to follow.†
Antibodies (also known as immunoglobulins) are gamma globulin proteins that are found in blood or other bodily fluids of vertebrates, and are used by the immune system to identify and neutralize foreign objects, such as bacteria and viruses.
The recently completed studies were conducted by independent researchers and were designed to test PAT-SM6's ability to prevent the metastatic spread of colon cancer to the liver.
The natural human antibody PAT-SM6 has been shown to have potent anti-cancer properties in a large number of laboratory and animal studies. PAT-SM6 binds to a proprietary cancer associated disease target that is expressed on the surface of cancer cells but not healthy tissues.
In the 19 animals treated with PAT-SM6, the median number of tumours that spread from the colon to the liver was decreased by approximately 50% as compared to the corresponding control group. This statistically significant result demonstrates the promise of PAT-SM6 as an effective treatment for the prevention of colon cancer metastases.
Dr. Christoph Otto, a medical oncologist and one of the lead investigators for the preclinical studies, said "the results of these studies indicate that PAT-SM6 offers great potential in terms of preventing colon cancer metastases, which is critically important because in most cases it is the spread of colon cancer to other organs that ultimately kills the patient."
"Products with this type of therapeutic potential are in high demand from the medical community given that currently approved cancer treatments are largely ineffective at preventing such metastases," added Dr. Otto.
Dr. Frank Hensel, Patrys' Vice President, Research and Development, added "the result of these studies reinforces earlier reported results where PAT-SM6 showed the ability to prevent the spread of gastric cancer in preclinical animal studies. Looking forward, the ability of PAT-SM6 to consistently perform in these studies across a number of different cancers gives our team added confidence in the endpoints we hope to achieve in the upcoming human clinical trial for PAT-SM6."
Patrys has now screened PAT-SM6 against more than 200 tumours from individual patients with various cancers, and the product binds to over 90% of the tumours screened regardless of the patient's cancer type, age, gender or disease stage. Patrys has filed patent applications to cover the PAT-SM6 molecule, its disease target, and its mechanism of action.